Reginald Gohh

Reginald Gohh

Auto-generated profile, based on publicly available information

Reginald Gohh

Rhode Island Hospital, Providence, Rhode Island

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
GRGohh R.Y
Gohh R.Y
YAYango A.F
Yango A.F
PMP. E. Morrissey
P. E. Morrissey
AMA. P. Monaco
A. P. Monaco
AGA. Gautam
A. Gautam
VSV. J. Savin
V. J. Savin
Recurrent focal segmental glomerulosclerosis (FSGS) following transplantation is ascribed to the presence of a circulating FSGS permeability factor (FSPF). Plasmapheresis (PP) can induce remission of proteinuria in recurrent FSGS. This study addressed the efficacy of pre‐transplant PP in decreasing the incidence of recurrence in high‐risk patients. Ten patients at high‐risk for FSGS recurrence because of rapid progression to renal failure (n = 4) or prior transplant recurrence of FSGS (n = 6) underwent a course of 8 PP treatments in the peri‐operative period. Recurrences were identified by proteinuria >3 g/day and confirmed by biopsy. Seven patients, including all 4 with first grafts and 3 of 6 with prior recurrence, were free of recurrence at follow‐up (238–1258 days). Final serum creatinine in 8 patients with functioning kidneys averaged 1.53 mg/dL. FSGS recurred within 3 months in 3 patients, each of whom had lost prior transplants to recurrent FSGS. Two of these progressed to end‐stage renal disease (ESRD) and the third has significant renal dysfunction. Based on inclusion criteria, recurrence rates of 60% were expected if no treatment was given. Therefore, PP may decrease the incidence of recurrent FSGS in high‐risk patients. Definitive conclusions regarding optimal management can only be drawn from larger, randomized, controlled studies.

1 March 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
CTChristie P. Thomas
Christie P. Thomas
RDReem Daloul
Reem Daloul
KLKrista L Lentine
Krista L Lentine
RGReginald Gohh
Reginald Gohh
PAPrince Mohan Anand
Prince Mohan Anand
YCYasar Caliskan
Yasar Caliskan
The growing accessibility and falling costs of genetic sequencing techniques has expanded the utilization of genetic testing in clinical practice. For living kidney donation, genetic evaluation has been increasingly used to identify genetic kidney disease in potential candidates, especially in those of younger ages. However, genetic testing on asymptomatic living kidney donors remains fraught with many challenges and uncertainties. Not all transplant practitioners are aware of the limitations of genetic testing, are comfortable with selecting testing methods, comprehending test results, or providing counsel, and many do not have access to a renal genetic counselor or a clinical geneticist. Although genetic testing can be a valuable tool in living kidney donor evaluation, its overall benefit in donor evaluation has not been demonstrated and it can also lead to confusion, inappropriate donor exclusion, or misleading reassurance. Until more published data become available, this practice resource should provide guidance for centers and transplant practitioners on the responsible use of genetic testing in the evaluation of living kidney donor candidates.

1 September 2002 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
AYA. Yango
A. Yango
PMP. Morrissey
P. Morrissey
RGR. Gohh
R. Gohh
AWAyman Wahbeh
Ayman Wahbeh
AMA. Monaco
A. Monaco

12 March 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ACAnil Chandraker
Anil Chandraker
ARAnil Regmi
Anil Regmi
RGReginald Gohh
Reginald Gohh
ASAkhil Sharma
Akhil Sharma
EWE. Steve Woodle
E. Steve Woodle
DWDavid Wojciechowski
David Wojciechowski
Key Points: Posoleucel was generally safe, well tolerated, and associated with a greater reduction of BK viremia compared with placebo. BK viremia reduction occurred coincident with an increase in the circulating frequency of BK virus–specific T cells in posoleucel recipients. The presence and persistence of posoleucel was confirmed by T-cell receptor variable β sequencing. Background: Kidney transplant recipients with BK virus infection are at risk of developing BK virus–associated nephropathy, allograft rejection, and subsequent graft loss. There are no approved treatments for BK virus infection. Posoleucel is an off-the-shelf, allogeneic, multivirus-specific T-cell investigational therapy targeting BK virus, as well as five other opportunistic viruses: adenovirus, cytomegalovirus, Epstein–Barr virus, human herpesvirus 6, and John Cunningham virus. Methods: In this phase 2, double-blind study, kidney transplant recipients with BK viremia were randomized 1:1:1 to receive posoleucel weekly for 3 weeks and then every 14 days (bi-weekly dosing) or every 28 days (monthly dosing) or placebo for 12 weeks. Participants were followed for 12 weeks after completing treatment. The primary objective was safety; the secondary objective was plasma BK viral load reduction. Results: Sixty-one participants were randomized and dosed. Baseline characteristics were similar across groups. No deaths, graft-versus-host disease, or cytokine release syndrome occurred. The proportion of patients who had adverse events (AEs) judged by the investigators to be treatment-related was slightly lower in recipients of posoleucel: 20% (4 of 20 patients) and 18% (4 of 22) in those infused on a bi-weekly and monthly schedule, respectively, and 26% (5 of 19) in placebo recipients. None of the grade 3–4 AEs or serious AEs in any group were deemed treatment-related. No deaths, graft-versus-host disease, or cytokine release syndrome occurred. Three participants had allograft rejection, but none were deemed treatment-related by investigators. In posoleucel recipients, BK viremia reduction was associated with an increase in the circulating frequency of BK virus–specific T cells, and the presence and persistence of posoleucel was confirmed by T-cell receptor sequencing. Conclusions: Posoleucel was generally safe, well tolerated, and associated with a larger reduction of BK viremia compared with placebo. Limitations of this study include the relatively short duration of follow-up and lack of power to detect significant differences in clinical outcomes. Clinical Trial registry name and registration number: Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia, NCT04605484.

1 January 2015 in World Journal of Transplantation
Verified
Journal Article
Open access
BMBasma Merhi
Basma Merhi
GBGeorge Bayliss
George Bayliss
RGReginald Y Gohh
Reginald Y Gohh
Despite the introduction of potent immunosuppressive medications within recent decades, acute rejection still accounts for up to 12% of all graft losses, and is generally associated with an increased risk of late graft failure. Current detection of acute rejection relies on frequent monitoring of the serum creatinine followed by a diagnostic renal biopsy. This strategy is flawed since an alteration in the serum creatinine is a late clinical event and significant irreversible histologic damage has often already occurred. Furthermore, biopsies are invasive procedures that carry their own inherent risk. The discovery of non-invasive urinary biomarkers to help diagnose acute rejection has been the subject of a significant amount of investigation. We review the literature on urinary biomarkers here, focusing on specific markers perforin and granzyme B mRNAs, FOXP3 mRNA, CXCL9/CXCL10 and miRNAs. These and other biomarkers are not yet widely used in clinical settings, but our review of the literature suggests that biomarkers may correlate with biopsy findings and provide an important early indicator of rejection, allowing more rapid treatment and better graft survival.

11 May 2006 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
AGAmitabh Gautam
Amitabh Gautam
PMPaul E. Morrissey
Paul E. Morrissey
ABAndrew S. Brem
Andrew S. Brem
SFStaci A. Fischer
Staci A. Fischer
RGReginald Y. Gohh
Reginald Y. Gohh
AMAnthony P. Monaco
Anthony P. Monaco